Stephens Investment Management Group LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 40.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 269,511 shares of the medical device company’s stock after acquiring an additional 77,187 shares during the period. Stephens Investment Management Group LLC owned approximately 0.31% of DexCom worth $15,467,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. State Street Corp lifted its position in DexCom by 2.5% in the second quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock worth $113,374,000 after purchasing an additional 37,581 shares during the period. Schwab Charles Investment Management Inc. lifted its position in DexCom by 3.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 265,019 shares of the medical device company’s stock worth $12,967,000 after purchasing an additional 8,171 shares during the period. Peregrine Capital Management LLC lifted its position in DexCom by 24.5% in the third quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock worth $19,348,000 after purchasing an additional 77,868 shares during the period. Macquarie Group Ltd. lifted its holdings in shares of DexCom by 67.2% during the second quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock valued at $17,746,000 after acquiring an additional 97,479 shares during the period. Finally, Tirschwell & Loewy Inc. lifted its holdings in shares of DexCom by 1.1% during the third quarter. Tirschwell & Loewy Inc. now owns 270,595 shares of the medical device company’s stock valued at $13,239,000 after acquiring an additional 2,900 shares during the period.
In other news, Director Barbara Kahn sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $54.58, for a total transaction of $163,740.00. Following the sale, the director now owns 4,353 shares in the company, valued at approximately $237,586.74. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $54.67, for a total value of $89,385.45. Following the sale, the executive vice president now owns 65,049 shares in the company, valued at approximately $3,556,228.83. The disclosure for this sale can be found here. Insiders sold a total of 48,140 shares of company stock worth $2,743,281 in the last 90 days. Company insiders own 1.70% of the company’s stock.
Shares of DexCom, Inc. (NASDAQ:DXCM) opened at $55.74 on Thursday. The company has a market capitalization of $4,750.99, a P/E ratio of -97.79 and a beta of 0.21. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. DexCom, Inc. has a 12 month low of $42.62 and a 12 month high of $86.32.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://weekherald.com/2018/02/15/dexcom-inc-dxcm-stake-raised-by-stephens-investment-management-group-llc.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.